line 33, delete "Figure 35A" and insert
therefor -- Figure 33A --;

line 33, delete "Figure 35B" and insert
therefor -- Figure 33B --.

In the Claims:

Please cancel Claim 108. Please amend Claims 106, 110, 111
and 112 and add Claims 113-124 as follows:

106. (Twice amended) A method of treating TNFα-mediated disease,
other than disease resulting from infection, in a human com-
prising administering to the human an effective TNF-
inhibiting amount of an anti-TNF chimeric antibody, wherein
said anti-TNF chimeric antibody comprises a non-human
variable region or a TNF-binding portion thereof and a human
constant region.

110. (Twice amended) A method of treating TNFα-mediated disease,
other than disease resulting from infection, in a human com-
prising administering to the human an effective TNF-
inhibiting amount of an anti-TNF chimeric antibody, wherein
said anti-TNF chimeric antibody competitively inhibits
binding of TNF to [a] monoclonal antibody [selected from the
group consisting of A2 or] cA2.

111. (Twice amended) A method of treating TNFα-mediated disease,
other than disease resulting from infection, in a human com-
prising administering to the human an effective TNF-
inhibiting amount of an anti-TNF chimeric antibody, wherein
said anti-TNF chimeric antibody binds to [one or more
epitopes] at least one epitope included in amino acids
between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of
hTNF.

112. (Twice amended)   A method of treating TNFα-mediated disease, other than disease resulting from infection, in a human comprising administering to the human an effective TNF-inhibiting amount of chimeric anti-TNF antibody cA2.

113. (New)   A method of treating TNFα-mediated disease, other than disease resulting from infection, in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises a non-human variable region or a TNF-binding portion thereof and an IgG1 human constant region.

114. (New)   The method of Claim 113 wherein the non-human variable region is of murine origin.

115. (New)   The method of Claim 113 wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2.

116. (New)   The method of Claim 113 wherein said anti-TNF chimeric antibody does not bind to one or more epitopes included in amino acids 11-13, 37-42, 49-57 or 155-157 of SEQ ID NO.: 1 of hTNF.

117. (New)   A method of treating TNFα-mediated disease, other than disease resulting from infection, in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of TNF to monoclonal antibody cA2.

118. (New)   A method of treating TNFα-mediated disease, other than disease resulting from infection, in a human comprising

administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises an IgG1 constant region and binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.

119. (New)   The method of Claim 106 wherein the non-human variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.: 5.

120. (New)   The method of Claim 113 wherein the non-human variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.: 5.

121. (New)   The method of Claim 106 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.: 2 and SEQ ID NO.: 4.

122. (New)   The method of Claim 113 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.: 2 and SEQ ID NO.: 4.

123. (New)   A method of treating TNFα-mediated disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2 and said disease is selected from the group consisting of immune and autoimmune pathologies, inflammatory diseases, neurodegenerative diseases, malignant pathologies, and alcohol-induced hepatitis.